Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank82
3Y CAGR-9.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-9.7%/yr
vs +84.1%/yr prior
Acceleration
-93.8pp
Decelerating
Percentile
P82
Within normal range
vs 3Y Ago
0.7x
Contraction
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 17.82% |
| Q3 2025 | 3.72% |
| Q2 2025 | 0.19% |
| Q1 2025 | -20.10% |
| Q4 2024 | 10.89% |
| Q3 2024 | -5.85% |
| Q2 2024 | 10.13% |
| Q1 2024 | -2.19% |
| Q4 2023 | 9.98% |
| Q3 2023 | -1.76% |
| Q2 2023 | 8.47% |
| Q1 2023 | -8.51% |
| Q4 2022 | 24.17% |
| Q3 2022 | 11.09% |
| Q2 2022 | 5.84% |
| Q1 2022 | -19.59% |
| Q4 2021 | 25.75% |
| Q3 2021 | 7.31% |
| Q2 2021 | 2.24% |
| Q1 2021 | 33.64% |
| Q4 2020 | -7.16% |
| Q3 2020 | -6.14% |
| Q2 2020 | -5.17% |
| Q1 2020 | -37.41% |
| Q4 2019 | 92.77% |
| Q3 2019 | 3.33% |
| Q2 2019 | 1.20% |
| Q1 2019 | -40.75% |
| Q4 2018 | 33.06% |
| Q3 2018 | 1.19% |
| Q2 2018 | 10.31% |
| Q1 2018 | -19.31% |
| Q4 2017 | 33.62% |
| Q3 2017 | -0.05% |
| Q2 2017 | 3.39% |
| Q1 2017 | -8.93% |
| Q4 2016 | 20.70% |
| Q3 2016 | -7.53% |
| Q2 2016 | 0.82% |
| Q1 2016 | -1.79% |